Iqvia Holdings Inc (NYSE:IQV) Director John Connaughton sold 1,441,236 shares of Iqvia stock in a transaction on Friday, June 15th. The stock was sold at an average price of $103.00, for a total value of $148,447,308.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of NYSE:IQV opened at $105.61 on Thursday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.16 and a current ratio of 1.16. The stock has a market cap of $21.64 billion, a price-to-earnings ratio of 24.22, a price-to-earnings-growth ratio of 1.75 and a beta of 0.64. Iqvia Holdings Inc has a 1 year low of $87.45 and a 1 year high of $110.67.
Iqvia (NYSE:IQV) last issued its quarterly earnings results on Wednesday, May 2nd. The medical research company reported $1.34 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.27 by $0.07. The company had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.42 billion. Iqvia had a net margin of 13.07% and a return on equity of 13.35%. Iqvia’s revenue for the quarter was up 34.1% compared to the same quarter last year. analysts anticipate that Iqvia Holdings Inc will post 5.07 EPS for the current fiscal year.
Several brokerages recently issued reports on IQV. Zacks Investment Research upgraded shares of Iqvia from a “strong sell” rating to a “hold” rating in a report on Friday, March 23rd. ValuEngine lowered shares of Iqvia from a “buy” rating to a “hold” rating in a report on Tuesday, April 3rd. SunTrust Banks upgraded shares of Iqvia from a “hold” rating to a “buy” rating in a report on Wednesday, March 7th. Goldman Sachs Group upgraded shares of Iqvia from a “neutral” rating to a “buy” rating in a report on Friday, April 13th. Finally, Argus boosted their price objective on shares of Iqvia from $110.00 to $112.00 and gave the company a “buy” rating in a report on Monday, April 9th. Six investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $110.47.
Iqvia Company Profile
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.